KNSA Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 69.44
- PEG ratio
- —
- P/B
- 8.87
- P/S (TTM)
- 6.90
- EV/EBITDA
- 51.78
Profitability & growth
- ROE (TTM)
- 14.0%
- Operating margin
- 11.2%
- Revenue growth YoY
- 55.4%
- Dividend yield
- —
- Beta
- 0.07
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Kiniksa Pharmaceuticals Ltd
Company profileKiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing breakthrough therapies to address pressing unmet medical needs, particularly in the realm of autoimmune disorders. Its flagship candidate, KPL-404, is a monoclonal antibody designed to effectively modulate immune responses, positioning Kiniksa at the forefront of promising therapeutic advancements. The company boasts a strong clinical pipeline supported by strategic partnerships that enhance its research and development capabilities. With a dedication to transforming treatment paradigms and a…
Classification
- Sector
- Healthcare
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 105 PICCADILLY, LONDON, UNITED KINGDOM
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
